Cytomegalovirus induced hemophagocytic lymphohistiocytosis: diagnostic and treatment challenges for the future

References

• Hayden A, Lin M, Park S, et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv. 2017;1(26):2529–2534.
   PubMed Web of Science ®Google Scholar
• Lin M, Park S, Hayden A, et al. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017;96(8):1241–1251.
   PubMedGoogle Scholar
• La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–2477.
   PubMed Web of Science ®Google Scholar
• Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89(11):4100–4103.
   PubMed Web of Science ®Google Scholar
• Zinter MS, Hermiston ML. Calming the storm in HLH. Blood. 2019;134(2):103–104.
   PubMedGoogle Scholar
• Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020;34(4):101515.
   PubMed Web of Science ®Google Scholar
• Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013;2013:605–611.
   PubMedGoogle Scholar
• Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288–297.
   PubMed Web of Science ®Google Scholar
• Brambilla B, Barbosa AM, Scholze CDS, et al. Hemophagocytic lymphohistiocytosis and inflammatory bowel disease: case report and systematic review. Inflamm Intest Dis. 2020;5(2):49–58.
   PubMedGoogle Scholar
• Li Y, Xia X, Zhang J, et al. Haemophagocytic lymphohistiocytosis in inflammatory bowel disease with virus infection. Prz Gastroenterol. 2015;10(2):78–82.
   PubMedGoogle Scholar
• Rolsdorph LÅ, Mosevoll KA, Helgeland L, et al. Concomitant hemophagocytic lymphohistiocytosis and cytomegalovirus disease: a case based systemic review. Front Med (Lausanne). 2022;9. DOI:10.3389/fmed.2022.819465.
   PubMedGoogle Scholar
• Reiner AP, Spivak JL. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore). 1988;67(6):369–388.
   PubMedGoogle Scholar
• Allen CE, McClain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program. 2015;2015:177–182.
   PubMedGoogle Scholar
• Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–4052.
   PubMed Web of Science ®Google Scholar
• Fardet L, Lambotte O, Meynard JL, et al. Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. AIDS. 2010;24(9):1299–1306.
   PubMedGoogle Scholar
• Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929.
   PubMed Web of Science ®Google Scholar
• Atim-Oluk M. Cytomegalovirus associated haemophagocytic lymphohistiocytosis in the immunocompetent adult managed according to HLH-2004 diagnostic using clinical and serological means only. Eur J Microbiol Immunol (Bp). 2013;3(1):81–89.
   PubMedGoogle Scholar
• Dioverti MV, Razonable RR, Hayden RT. Cytomegalovirus. Microbiol Spectr. 2016;4(4). DOI:10.1128/microbiolspec.DMIH2-0022-2015
   PubMed Web of Science ®Google Scholar
• Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL study group of the histiocyte society. Semin Oncol. 1991;18(1):29–33.
   PubMed Web of Science ®Google Scholar
• Henter JI, Aricò M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study group of the histiocyte society. Med Pediatr Oncol. 1997;28(5):342–347.
   PubMedGoogle Scholar
• Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125(19):2908–2914.
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–e272.
   PubMed Web of Science ®Google Scholar
• Morimoto A, Nakazawa Y, Ishii E. Hemophagocytic lymphohistiocytosis: pathogenesis, diagnosis, and management. Pediatr Int. 2016;58(9):817–825.
   PubMed Web of Science ®Google Scholar
• Ozbalak M, Mastanzade MG, Gurel E, et al. Cytomegalovirus reactivation during adult acute lymphoblastic leukemia maintenance: do we underestimate (un)expected guest of pediatric approach? Am J Blood Res. 2021;11(1):118–122.
   PubMedGoogle Scholar
• Goel S, Polski JM, Imran H. Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis. Ann Clin Lab Sci. 2012;42(1):21–25.
   PubMed Web of Science ®Google Scholar
• Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620.
   PubMed Web of Science ®Google Scholar
• Divithotawela C, Garrett P, Westall G, et al. Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor - anakinra. Respirol Case Rep. 2016;4(1):4–6.
   PubMedGoogle Scholar
• Bami S, Vagrecha A, Soberman D, et al. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2020;67(11):e28581.
   PubMedGoogle Scholar
• Wohlfarth P, Agis H, Gualdoni GA, et al. Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically Ill adult patients with hemophagocytic lymphohistiocytosis. J Intensive Care Med. 2019;34(9):723–731.
   PubMed Web of Science ®Google Scholar
• Wang H, Gu J, Liang X, et al. Low dose ruxolitinib plus HLH-94 protocol: a potential choice for secondary HLH. Semin Hematol. 2020;57(1):26–30.
   PubMedGoogle Scholar
• Hansen S, Alduaij W, Biggs CM, et al. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: a case series. Eur J Haematol. 2021;106(5):654–661.
   PubMed Web of Science ®Google Scholar